Postvaccination Serum Antirotavirus Immunoglobulin A as a Correlate of Protection Against Rotavirus Gastroenteritis Across Settings
- PMID: 32060525
- PMCID: PMC7323497
- DOI: 10.1093/infdis/jiaa068
Postvaccination Serum Antirotavirus Immunoglobulin A as a Correlate of Protection Against Rotavirus Gastroenteritis Across Settings
Abstract
Background: A correlate of protection for rotavirus gastroenteritis would facilitate rapid assessment of vaccination strategies and the next generation of rotavirus vaccines. We aimed to quantify a threshold of postvaccine serum antirotavirus immunoglobulin A (IgA) as an individual-level immune correlate of protection against rotavirus gastroenteritis.
Methods: Individual-level data on 5074 infants in 9 GlaxoSmithKline Rotarix Phase 2/3 clinical trials from 16 countries were pooled. Cox proportional hazard models were fit to estimate hazard ratios (HRs) describing the relationship between IgA thresholds and occurrence of rotavirus gastroenteritis.
Results: Seroconversion (IgA ≥ 20 U/mL) conferred substantial protection against any and severe rotavirus gastroenteritis to age 1 year. In low child mortality settings, seroconversion provided near perfect protection against severe rotavirus gastroenteritis (HR, 0.04; 95% confidence interval [CI], .01-.31). In high child mortality settings, seroconversion dramatically reduced the risk of severe rotavirus gastroenteritis (HR, 0.46; 95% CI, .25-.86). As IgA threshold increased, risk of rotavirus gastroenteritis generally decreased. A given IgA threshold provided better protection in low compared to high child mortality settings.
Discussion: Postvaccination antirotavirus IgA is a valuable correlate of protection against rotavirus gastroenteritis to age 1 year. Seroconversion provides an informative threshold for assessing rotavirus vaccine performance.
Keywords: correlate of protection; gastroenteritis; immunoglobulin A; rotavirus; vaccination.
Published by Oxford University Press for the Infectious Diseases Society of America 2020.
Figures

References
-
- International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health. VIEW-hub. PCV-vaccine introduction. Current vaccine intro status. http://view-hub.org/viz/. Accessed 18 February 2020.
-
- International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health. Gap analysis of rotavirus vaccine impact evaluations in settings of routine use, 2017https://www.jhsph.edu/ivac/wp-content/uploads/2018/04/RVImpactGapAnalysi.... Accessed 18 February 2020.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous